Public Health | April 18, 2026
Experts endorse low-sodium salt substitutes to cut India’s hypertension burden
Consensus calls for nationwide adoption of potassium-enriched salt to reduce cardiovascular disease risk
Consensus calls for nationwide adoption of potassium-enriched salt to reduce cardiovascular disease risk
The enhanced allocation will be directed toward expanding healthcare infrastructure, increasing patient capacity, and widening acces
Landmark procedure restores 32-year-old CKD patient’s health, highlighting how public insurance is widening access to advanced renal care
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
The study, which enrolled 35 Japanese patients, evaluated the percent change from baseline in the 24-hour urine protein-to-creatinine ratio
Renalyx will continue operating as an independent unit within the group
Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
The ALLEGORY study demonstrated statistically significant improvements in key measures, including British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response
Subscribe To Our Newsletter & Stay Updated
